Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L. Simpson, Rodney Sinclair, Seth Forman, Andreas Wollenberg, Roland Aschoff, Michael J. Cork, Thomas Bieber, Jacob P. Thyssen, Gil Yosipovitch, Carsten Flohr, Nina Magnolo, Catherine Maari, Claire Feeney, Pinaki Biswas, Svitlana Tatulych, Hernán Valdez, Ricardo Rojo
Topics & Concepts
Eczema Area and Severity IndexMedicineAtopic dermatitisPlaceboAdverse effectRandomized controlled trialInternal medicineClinical trialJanus kinase inhibitorClinical endpointSeverity of illnessPhysical therapyPediatricsDermatologyPathologyRheumatoid arthritisTofacitinibAlternative medicineDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisAsthma and respiratory diseases